The goal of this study is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease.
Healthy male and female (Part 1-2 only) participant, aged ≥ 18 to ≤ 55 years.
Female participant of childbearing potential (Part 1-2 only)
Female participant of non-childbearing potential (Part 1-2 only).
Female participant (Part 1-2 only) with a negative pregnancy test at Screening visit.
A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
Use of prescription or non-prescription drugs, excluding allowable drugs and contraception
Reports having experienced suicidal ideation (Type 4 on 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS©] him/herself or others - Part 2 only.
Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
Mission Therapeutics
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Collaborator
Parkinson's UK
Collaborator